Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950157-25-000596
Filing Date
2025-07-30
Accepted
2025-07-30 17:56:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 5339
  Complete submission text file 0000950157-25-000596.txt   7350
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filed by) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Subject) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88275 | Film No.: 251168429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)